PROCESS FOR THE PREPARATION OF (1S,4R)-CIS-4'-2-AMINO-6CHLORO-9H-PURIN-9-YL!-2-CYCLOPENTENE-1-METHANOL

Abstract: A process for preparing a chloropurine compound of formula (I) or a derivative thereof, which comprises ring closure of the compound of formula (VII) or a derivative thereof in the presence of catalytic acid and at least one equivalent of a formate derivative.
The present invention relates to a novel process for the preparation of a chloropurine compound of formula (I) or a derivative thereof.

\[
(1S,4R)-\text{cis-4-[2-Amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol,}
\]

The chloropurine compound of formula (I)

\[
\text{(I)}
\]

is described in European Patent No. 0 325 460 and can be used as an intermediate in the manufacture of abacavir ((1S,4R)-\text{cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol}), a 2-aminopurine nucleoside compound of formula (II)

\[
\text{(II)}
\]

The antiviral use of abacavir, particularly in the treatment of the human immunodeficiency virus (HIV), is described in European Patent No. 0 434 450 and the hemisulfate salt of abacavir, described in International Patent Application No. WO98/52949, is commercially available from GlaxoSmithKline for the treatment of HIV under the tradename ZIAGEN®.

Processes for preparing abacavir and intermediates useful in the synthesis of abacavir have been described by, for example, Daluge et al. in Nucleosides, Nucleotides & Nucleic Acids, 19 (1&2), 2000, 297-327. International Patent Application No. WO99/19327 describes an in situ process for the preparation of the chloropurine compound of formula (I) which comprises hydrolysing a compound of formula (III)
wherein P is a protecting group, in the presence of an acid, condensing the product of formula (IV) formed

\[ \text{(IV)} \]

\[ \text{HO-} \]
\[ \text{NHP} \]

in situ in the presence of a base with a compound of formula (V)

\[ \text{(V)} \]

\[ \begin{array}{c}
\text{Cl} \\
\text{NHR} \\
\text{H}_2\text{N} \\
\text{Cl} \\
\end{array} \]

in which R represents CHO or H, followed by ring closure in situ of the resulting intermediate of formula (VI)

\[ \text{(VI)} \]

\[ \begin{array}{c}
\text{Cl} \\
\text{NHR} \\
\text{H}_2\text{N} \\
\text{H} \\
\text{CH}_2\text{OH} \end{array} \]

According to WO99/19327, the ring closure reaction is preferably carried out in the presence of from about 1.5 to 3 molar equivalents of hydrochloric acid and a large excess of triethylorthoformate, which results in precipitation of the hydrochloride salt of the chloropurine compound of formula (I).

As abacavir is sold as a prescription medicine for the treatment of HIV infections, there exists a need to develop more efficient processes for preparing the compound in large quantities.

We have now found a process for preparing the chloropurine compound of formula (I) or a derivative thereof in which the amount of both the acid and formate derivative used
in the cyclisation step is significantly reduced. The process according to the present invention thus allows abacavir and derivatives thereof to be prepared without isolation of the highly toxic hydrochloride salt of the chloropurine compound of formula (I), which can be difficult to filter, and avoids the problems associated with handling gaseous hydrogen chloride. As a result, the process according to the present invention is a safer process in which the amount of solvent used is lowered, minimising waste and environmental impact, the cycle time is reduced, and the throughput and overall yield of the process is increased.

Accordingly, the present invention provides a process for preparing a chloropurine compound of formula (I)

![Chemical Structure of Formula I](image)

or a derivative thereof, which comprises ring closure of the compound of formula (VII) or a derivative thereof

![Chemical Structure of Formula VII](image)

in the presence of catalytic acid and at least one equivalent of a formate derivative.

Acids suitable for use in the process of the present invention include concentrated aqueous and anhydrous mineral acids, for example sulfuric acid, hydrochloric acid, or an alkyl or arylsulfonic acid. Preferably, the acid is sulfuric acid. In order to effect ring closure, the acid is present in a catalytic amount. Typically, the acid is present in an amount of up to 0.2 equivalents by mole based on the amount of the compound of formula (VII), for example up to 0.1 equivalents by mole. In one embodiment, the acid is present in an amount of from 0.05 to 0.1 equivalents. In another embodiment, the acid is present in an amount of from 0.01 to 0.05 equivalents. In a further embodiment, the acid is present in an amount of about 0.05 equivalents.
Formate derivatives suitable for use in the process of the present invention include trialkyloformates such as trimethylorthoformate or triethylorthoformate, and diethoxyethylacetate. Preferably, the formate derivative is triethylorthoformate. In the process of the present invention, the formate derivative is present in an amount of at least one equivalent by mole based on the amount of the compound of formula (VII), preferably from 1 to 5 equivalents, more preferably from 1 to 2 equivalents and most preferably from 1 to 1.5 equivalents.

The ring closure reaction is preferably carried out in an anhydrous polar aprotic solvent, for example acetonitrile, anhydrous dimethylacetamide, dimethylformamide, or an alkanol solvent such as methanol, ethanol, n-butanol, iso-propanol (IPA) or industrial methylated spirit (IMS), in particular n-butanol. The reaction mixture is generally heated to a temperature of from 20 to 100°C, preferably from 40 to 80°C and more preferably from 60 to 70°C, for at least 3 hours.

The compound of formula (VII) may be prepared by condensing an amino alcohol of formula (IV) as hereinbefore defined or a derivative thereof with a compound of formula (VIII) or a derivative thereof

\[ \text{(VIII)} \]

in the presence of a base.

The base is generally a trialkylamine such as triethylamine or an alkali metal carbonate or bicarbonate such as potassium or sodium carbonate or bicarbonate. Preferably, the base is an alkali metal bicarbonate such as potassium or sodium bicarbonate, in particular sodium bicarbonate. The base is present in an amount at least sufficient to neutralise the acid produced in the condensation reaction. Generally, there will be at least 2 equivalents by mole of base based on the amount of the compound of formula (IV), preferably from 2.2 to 5 equivalents, more preferably about 2.5 equivalents.

The condensation reaction between the compound of formula (IV) and the compound of formula (VIII) may be carried out under reflux in a polar solvent such as an alkanol, for example, methanol, ethanol, n-butanol, IPA or IMS, ethyl acetate or acetonitrile. Preferably, the condensation reaction is carried out in n-butanol. The reaction mixture is generally heated to a temperature of from 60 to 110°C, preferably from 80 to 110°C and more preferably from 90 to 100°C, for at least 8 hours.

After the condensation reaction is complete, the reaction mixture may be diluted and filtered at a temperature of at least 70°C. In one embodiment, the reaction mixture is filtered through charcoal. The filtrate may be concentrated and used in the ring closure reaction without further purification.
In a preferred embodiment of the present invention, the condensation reaction is carried out in n-butanol in the presence of sodium bicarbonate. Preferably, once the condensation reaction is complete, the reaction mixture is diluted, filtered and then concentrated. In one embodiment, the volume of solvent is reduced by at least 50%, for example from 50 to 60%. In a further embodiment, the volume of solvent is reduced by at least 10%, for example from 10 to 30%.

In a further embodiment of the present invention, the condensation reaction is carried out in n-butanol in the presence of anhydrous potassium carbonate. The potassium carbonate removes the liberated water from solution thus avoiding the need for a concentration step.

The compound of formula (IV) may be prepared by the procedure described in WO99/19327 and the compound of formula (VIII) may be prepared by the procedure described in WO95/21161 and WO99/19327.

According to the process of the present invention, the ring closure reaction results in the formation of the chloropurine compound of formula (I) or a derivative thereof. As the acid used in the ring closure reaction is only present in a catalytic amount, the chloropurine compound does not precipitate out as a salt but remains in solution. Thus, the chloropurine compound can be converted in situ to abacavir or a derivative thereof.

In one embodiment, the chloropurine compound of formula (I) or derivative thereof is converted to abacavir or a derivative thereof by treatment of the reaction mixture with cyclopropylamine. The abacavir or derivative thereof may be isolated from the reaction mixture, for example by addition of glutaric acid to form the glutarate salt. The isolated abacavir or derivative thereof may then be converted to abacavir hemisulfate by, for example, the procedures described in WO98/52949.

When used herein, the term "pharmaceutically acceptable" means a derivative which is suitable for pharmaceutical use. Salts and solvates which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other derivatives.

When used herein, the term "pharmaceutically acceptable derivative", means any pharmaceutically acceptable salt, solvate, or prodrug e.g. ester, which upon administration to the recipient is capable of providing (directly or indirectly) the compound, or an active metabolite or residue thereof. Such derivatives are recognizable to those skilled in the art, without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives. Preferred pharmaceutically acceptable derivatives are salts, solvates, esters, carbamates and phosphate esters. Particularly preferred pharmaceutically acceptable derivatives are salts, solvates and esters. Most preferred pharmaceutically acceptable derivatives are salts and esters, especially salts.
When used herein, the term “derivative”, means any pharmaceutically acceptable derivative or non-pharmaceutically acceptable derivative which is suitable for use in the process of the present invention. The skilled person will appreciate that non-pharmaceutically acceptable derivatives may be used to prepare compounds and derivatives suitable for pharmaceutical use. In one embodiment, the derivatives used or prepared according to the present invention are pharmaceutically acceptable derivatives.

Compounds prepared using the process of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt. For a review on suitable salts see Berge et al., J. Pharm. Sci., 1977, 66, 1-19.

Typically, a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Salts prepared using the process of the present invention may, for example, comprise acid addition salts resulting from reaction of an acid with a basic nitrogen atom. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Suitable addition salts are formed from acids which form non-toxic salts and examples are acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, bromide, calcium edetate, camysylate, carbonate, chloride, clavulanate, citrate, cyclohexylsulfamate, dihydrochloride, edetate, edisylate, estolate, esylate, ethanesulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, gluconate, glycollate, glycollylarsanilate, hemisulfate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogen phosphate, hydroiodide, hydroxynaphthoate, iodide, isethionate, itaconate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxalacetate, pamoate (embonate), palmate, palmitate, pantethenate, phosphate/diphosphate, piruvate, polygalacturonate, propionate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartarate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate. Preferred salts prepared according to the present invention include the succinate, glutarate and hemisulfate salts.

Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. For example, a complex with water is known as a “hydrate”. Solvates are within the scope of the invention. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water.

When used herein, the term “prodrug” means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella; Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward

Prodrugs are any covalently bonded carriers that release the compound in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds wherein the amine group is bonded to any group that, when administered to a patient, cleaves to form the amine group. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of the amine functional group.

When used herein, the term "alkyl" refers to straight and branched groups containing up to six carbon atoms. Examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl or hexyl.

When used herein, the term "aryl" refers to, unless otherwise defined, single or fused aromatic rings suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring. A fused ring system may include aliphatic rings and need only include one aromatic ring. Examples of suitable aryl rings include phenyl and naphthyl.

When used herein, the term "alkanol" refers to C1-g alkyl alcohols, for example methanol, ethanol, industrially methylated spirit (IMS), n-propanol, iso-propanol (IPA), n-butanol, pentanol, hexanol, heptanol, octanol or nonanol, in particular methanol, ethanol, IMS, IPA or n-butanol.

The invention is illustrated by the following Examples.

**EXAMPLES**

HPLC was carried out using the following conditions:

Luna 3µm C18 50mm x 2.0mm Reverse Phase Column
Solvent A = Water/0.05%TFA
Solvent B = Acetonitrile/0.05%TFA
Gradient profile, 0.00 min = 0% Solvent B; 8.00min = 95% Solvent B
Flow rate = 1.0 ml/min
Temperature = 40°C
Injection Volume = 1.0µl

**Example 1**

DADCP (2,5-diamino-4,6-dichloropyrimidine) (400g, 1.0eq), [(1S,4R)-4-amino-2-cyclopenten-1-yl]methanol hydrochloride (aminoalcohol.HCl) (336g, 1.0eq), sodium bicarbonate (644g, 3.5eq) and n-butanol (3.2L) were heated together at 95-100°C for 8h.
The mixture was diluted with n-butanol 6.8L, cooled to 75-80°C and inorganics were removed by filtration. The cake was washed with n-butanol (2 x 600ml).

The combined filtrate was concentrated down to ca 4L then diluted with n-butanol (2.4L). Triethylorthoformate (368ml, 1.2eq) and catalytic sulfuric acid (4ml, 0.05eq) were added and the mixture was heated at 65-70°C for 6h.

Cyclopropylamine (648ml, 4.2eq) was added at about 40-45°C and the mixture was heated at 65-70°C for 5h. The reaction mixture was cooled to 20-25°C then anhydrous sodium carbonate (480g, 2eq) was added and the slurry stirred for 1h. The inorganics were removed by filtration and the cake washed with butanol (2 x 800ml). The filtrate was concentrated to ca 7.5L to remove excess cyclopropylamine then heated to 110-115°C. A solution of glutaric acid (296g) in butanol (2L) was added over 5 mins keeping the temp > 105°C. Cooled to 100-105°C then seeded with authentic abacavir glutarate. The resultant slurry was allowed to cool to 2-5°C over at least 2h, then aged @ 2-5°C for 18h. The product was collected by vacuum filtration, the cake washed with cold IPA (3 x 800ml) and dried in-vacuo at t 50°C to give a bacavir glutarate (82%, purity by HPLC 98.0%a/a). LCMS MH⁺ 287, retention time 2.46 min.

Example 2

DADCP (1wt, 1.0eq), [(1S,4R)-4-amino-2-cyclopenten-1-yl]methanol hydrochloride (aminoalcoholHCl) (0.88wt, 1.05eq), sodium bicarbonate (1.17wt, 2.5eq) and n-butanol (6vol) were heated together at 95-100°C for ca 10h. The reaction mixture was sampled for analysis by generic LC (complete when residual DADCP <0.5%a/a @ 220nm). The mixture was diluted with butanol (10vol), then cooled to 85-90°C and the inorganics were removed by filtration. The hot filtrate (>70°C) was passed through a jacketed Cuno filter containing Charcoal (Norit A Supra Eur, 0.04wt). The cake was washed with hot n-butanol (2 x 2vols) ensuring that the temp >70°C.

The combined filtrate was concentrated down to ca 8 vols by vacuum distillation to remove water (collected ca. 12vols), the temperature adjusted to 65-70°C then triethylorthoformate (1.01vol, 1.1eq) and sulfuric acid (0.01vol, 0.05eq) were added. The mixture was heated at 65-70°C for 3h then sampled for analysis by generic LC.

The reaction mixture was cooled to 45-50°C, cyclopropylamine (1.62vol, 4.2eq) was added and the mixture heated up to 85-90°C at which it was stirred for 2h. The reaction mixture was sampled for analysis by generic LC (complete when residual chloropurine <0.5%a/a @ 220nm). Butanol (4vol) was added and the reaction was concentrated to ca 7.5vols to remove excess cyclopropylamine (diluted and repeated as necessary), diluted with butanol (10vol) then heated to 75-80°C. A solution of glutaric acid (0.74wt) in butanol (5vol) was heated to 75°C and was added over 5 mins keeping the temp >75°C. Seeded with authentic abacavir glutarate and the resultant slurry was allowed to cool to 2-5°C over at least 2h, then aged @ 2-5°C for at least 1h. The product was collected by vacuum filtration, the cake washed with cold IPA (1 x 4vol then 2 x 3vol) and dried in-vacuo at 50°C to give abacavir glutarate (85%, purity by HPLC 98.7%a/a). LCMS MH⁺ 287, retention time 2.46 min.
CLAIMS

1. A process for preparing a chloropurine compound of formula (I)

\begin{align*}
\text{Cl} \\
\text{H}_2\text{N} \\
\text{N} \\
\text{N} \\
\text{N} \\
\text{H}_2\text{N} \\
\text{C}_\text{H}_2\text{OH}
\end{align*}

(I)

or a derivative thereof, which comprises ring closure of the compound of formula (VII) or a derivative thereof

\begin{align*}
\text{Cl} \\
\text{N} \\
\text{N} \\
\text{N} \\
\text{N} \\
\text{H}_2\text{N} \\
\text{H}_2\text{N} \\
\text{C}_\text{H}_2\text{OH}
\end{align*}

(VII)

in the presence of catalytic acid and at least one equivalent of a formate derivative.

2. A process according to claim 1 wherein the acid is sulfuric acid, hydrochloric acid, or an alkyl or arylsulfonic acid.

3. A process according to claim 1 or claim 2 wherein the acid is present in an amount of from 0.05 to 0.1 equivalents by mole based on the amount of the compound of formula (VII).

4. A process according to any one of the preceding claims wherein the formate derivative is triethylorthoformate.

5. A process according to any one of the preceding claims wherein the formate derivative is present in an amount of 1 to 1.5 equivalents by mole based on the amount of the compound of formula (VII).
6. A process according to any one of the preceding claims wherein the compound of formula (VII) or a derivative thereof is prepared by condensing an amino alcohol of formula (IV) or a derivative thereof

\[
\text{HO-}\begin{array}{c}
\text{NH}_2
\end{array}
\text{ (IV)}
\]

with a compound of formula (VIII) or a derivative thereof

\[
\text{Cl-}\begin{array}{c}
\text{NH}_2
\end{array} \quad \text{H}_2\text{N} \quad \text{Cl-}\begin{array}{c}
\text{NH}_2
\end{array}
\text{ (VIII)}
\]

in the presence of a base.

7. A process according to claim 6 wherein the condensation reaction is carried out in n-butanol in the presence of sodium bicarbonate.

8. A process according to claim 6 wherein the condensation reaction is carried out in n-butanol in the presence of anhydrous potassium carbonate.

9. A process according to any one of the preceding claims wherein the chloropurine compound of formula (I) or derivative thereof prepared by the ring closure reaction is converted \textit{in situ} to abacavir or a derivative thereof.

10. A process according to any one of the preceding claims substantially as hereinbefore defined with reference to the Examples.
### INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

**IPC 7:** C07D 473/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC 7:** C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 00/19327 A (ACTIONTEC ELECTRONICS INC) 6 April 2000 (2000-04-06) cited in the application examples A-D</td>
<td>1-10</td>
</tr>
<tr>
<td></td>
<td>EP 0 628 044 A (WELLCOME FOUND) 14 December 1994 (1994-12-14) example 25</td>
<td>1-10</td>
</tr>
<tr>
<td>A</td>
<td>EP 0 741 710 A (WELLCOME FOUND) 13 November 1996 (1996-11-13) example 11b</td>
<td>1-10</td>
</tr>
</tbody>
</table>

---

X Further documents are listed in the continuation of box C.  
X Patent family members are listed in annex.

---

* Special categories of cited documents:

*A* document defining the general state of the art which is not considered to be of particular relevance  
*E* earlier document but published on or after the international filing date  
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
*O* document referring to an oral disclosure, use, exhibition or other means  
*P* document published prior to the international filing date but later than the priority date claimed

**I** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
**X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
**Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
*SX* document member of the same patent family

Date of the actual completion of the international search: 13 December 2004

Date of mailing of the international search report: 21/01/2005

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 940-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer: Baston, E
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6057599 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TW 432328 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0019327 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 707075 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2489197 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 3571093 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2130755 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69333109 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69333109 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 628044 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0628044 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2203615 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9317020 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1003941 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3172533 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 7504185 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 628044 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2001008946 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5641889 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5840990 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5919941 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5808147 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 690203 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1543895 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9506667 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69516847 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69516847 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 741710 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 963070 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3033850 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1004087 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 75300 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9508412 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 963239 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 278948 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 315713 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2140913 C1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI 741710 T1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6448403 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5917041 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2182105 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1388123 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1139924 A ,B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2148486 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9521161 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 112539 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 741710 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 47918 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TW 390877 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2002173649 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003187263 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6552193 B1</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5917042 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6555687 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9500884 A</td>
</tr>
</tbody>
</table>